Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 15/20 | 0.78 |
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8322692 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL11316399 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL8319523 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL11323835 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL25228937 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL8397082 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL25277323 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL25228539 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL24285430 | 1.00 | EPHX1 (0.78) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL7434396 | 0.98 | EPHX1 (0.74) | EPHX1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296897-A | PPAR-modulating biaromatic compounds | GALDERMA RES & DEV (FR) | 2008-10-29 | — | — | CN | claimed |
| CN-101022810-A | Novel biaromatic compounds which activate peroxisome proliferator activated receptor-like receptors and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2007-08-22 | — | — | CN | claimed |
| CN-1984892-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | claimed |
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| US-20230242808-A1 | PHOTOCHROMIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| WO-2023136213-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2023-07-20 | — | — | WO | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-20230133211-A1 | PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC CYCLIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4130090-A1 | CURABLE RESIN COMPOSITION AND METHOD FOR SUPPRESSING CURING SHRINKAGE OF CURABLE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4108735-A1 | PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING SAID PHOTOCHROMIC CYCLIC COMPOUND | Tokuyama Corporation (JP) | 2022-12-28 | — | — | EP | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5194660-A | Processes for producing carbamates and isocyanates | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1993-03-16 | — | — | US | disclosed |
| US-4929724-A | PHOSPHOROUS-NITROGEN DIMERIZATION CATALYSTS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-05-29 | — | — | US | disclosed |
| EP-0083096-B1 | PRODUCTION OF URETHANE COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-02-25 | — | — | EP | disclosed |
| US-4621149-A | PLATINUM GROUP METAL HALOGEN OR HALOGEN COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0083096-A2 | Production of urethane compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242808-A1 | PHOTOCHROMIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC COMPOUND | RB1, CRY2, CDK16 | EPHX1 3224/4885CASP2 1789/4885ZDHHC20 3215/4885 |
| US-20230133211-A1 | PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC CYCLIC COMPOUND | CRY1, CCNL2, CCNT1 | EPHX1 2227/4885CASP2 1603/4885ZDHHC20 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.